Brief: Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation For Descartes-08 For The Treatment Of Myasthenia Gravis
22/05/2024 12:05
Cartesian Therapeutics Inc RNAC.O :
* CARTESIAN THERAPEUTICS RECEIVES FDA REGENERATIVE MEDICINE
ADVANCED THERAPY (RMAT) DESIGNATION FOR DESCARTES-08 FOR THE
TREATMENT OF MYASTHENIA GRAVIS
* CARTESIAN- ON TRACK TO POST TOPLINE DATA FROM PHASE 2B
RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF DESCARTES-08 IN PATIENTS
WITH MG IN MID-2024
Source text for Eikon: ID:nGNXy1VPW
Further company coverage: RNAC.O
Recent news on Cartesian Therapeutics
See all newsBrief: Cartesian Therapeutics Announces Additional Retreatment Data For Descartes-08 Highlighting Deep And Durable Responses In Patients With Myasthenia Gravis
Cartesian Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cartesian Therapeutics Q2 net income steady
Brief: Cartesian Therapeutics Inc Q2 Net Income USD 15.769 Million
Cartesian Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview